Low-Dose Nedaplatin (CDGP:Cis-Diammine-Glycolatoplatinum)/5-FU Combined With Radiation for Esophageal Cancer

• Status: Completed
• Trial end date: 2008-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to clarify efficacy and toxicity of daily low-dose Nedaplatin (CDGP) and continuous infusion of 5-FU combined with radiation in patients with esophageal squamous cell carcinoma.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hamamatsu University
• Treatments: Fluorouracil; Nedaplatin

Criteria

Inclusion Criteria:

• newly diagnosed cases histologically as squamous cell carcinoma,

• a performance status 0 to 2,

• white blood cells >3,000/microL,

• platelets >100,000/microL,

• serum total bilirubin <2.0 mg/dl,

• serum transaminase <3 times the upper normal limit,

• serum creatinine <1.5 mg/dl,

• creatinine clearance >60 ml/min

Exclusion Criteria:

• serious cardiac disease

• prior chemotherapy and radiotherapy